Anaphylaxis and systemic mastocytosis controlled with KIT inhibitors in a patient with metastatic lung adenocarcinoma

Ann Allergy Asthma Immunol. 2023 Nov;131(5):668-670. doi: 10.1016/j.anai.2023.08.009. Epub 2023 Aug 18.

Authors

Camellia L Hernandez¹, Donna-Marie Lynch², Abby Jane Golash², Kathleen Marquis², Kylie Marie Besz², Geoffrey Oxnard³, Julia Rotow⁴, Daniel J DeAngelo⁴, Mariana Castells²

Affiliations

¹ Department of Allergy and Clinical Immunology, Brigham and Women's Hospital, Boston, Massachusetts. Electronic address: Chernandez28@bwh.harvard.edu.
² Department of Allergy and Clinical Immunology, Brigham and Women's Hospital, Boston, Massachusetts.
³ Department of Medical Oncology, Boston Medical Center, Boston, Massachusetts.
⁴ Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.

PMID: 37597693
DOI: 10.1016/j.anai.2023.08.009

No abstract available

MeSH terms

Adenocarcinoma of Lung* / drug therapy
Allergens
Anaphylaxis*
Humans
Lung Neoplasms* / drug therapy
Mast Cells
Mastocytosis*
Mastocytosis, Systemic* / drug therapy
Tryptases

Substances

Allergens
Tryptases